

June 14, 2024

To whom it may concern:

Company Name Corporate Representative	TOHO HOLDINGS CO., LTD. Atsushi Udoh, Representative Director, CEO (Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Corporate Officer and General Manager, Corporate Strategy Division (TEL: 81-3-6838-2803)

**Notice Regarding Change of Trade Names for 2 Ingredients
and 3 Products Manufactured and Sold by the Company**

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, CEO: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Yasuyuki Kumada), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has changed the trade names for “2 ingredients and 3 products manufactured and sold by the Company” and launch them under the new names owing to the filing of a new application for substitution today on June 14, 2024 as below.

List of products with changed trade name

Former Trade Name	New Product Name
Toaraset Combination Tablets “KYOSOMIRAI”	Toaraset Combination Tablets ”KMP”
Mirtazapine Tablets 15mg “KYOSOMIRAI”	Mirtazapine Tablets 15mg ”KMP”
Mirtazapine Tablets 30mg “KYOSOMIRAI”	Mirtazapine Tablets 30mg ”KMP”